Lucid Diagnostics Inc - רווח נקי למניה בארבעת הרבעונים האחרונים LUCD

Lucid Diagnostics Inc. (LUCD) is actively expanding the distribution of its diagnostic systems, focusing on securing agreements with insurance companies. The GURU.Markets quotes provided below for the EPS (TTM) metric are 54.80. The business attracts leading scientists through the prestige of its developments in combating esophageal oncology. Economic efficiency is achieved by centralizing laboratory processes, which reduces costs as the number of screenings increases.

Lucid Diagnostics Inc. (LUCD) leverages efficient medical logistics to accelerate cancer diagnostics, directly impacting operating revenue. These achievements translate into the calculated difference in net income per share over the last twelve months compared to the previous year. This metric measures the real dynamics of return on equity, excluding subjective forecasts. Analyzing the rolling change in earnings per share YoY allows for an objective assessment of the issuer's financial stability.